Johnson and Johnson receives CE mark for vascular reconstruction

Cordis Neurovascular, a subsidiary of Johnson and Johnson, has announced that the Cordis Enterprise Vascular Reconstruction Device and Delivery System has been awarded a CE Mark in Europe for the treatment of intracranial aneurysms when used with occlusive devices.

The device is approved for use in Europe to assist in endovascular neurointervention where coils are used to fill aneurysms for the facilitation of clot formation and occlude blood flow to reduce the possibility of an aneurysm rupture.

Cordis Neurovascular reports that its device operates by acting as a scaffold to secure these coils in place inside the aneurysm during the procedure. The company adds that clinical trials of the system show that it is a “promising assist device” in the treatment of intracranial aneurysms.

It ads that the device can aid physicians in the recapturing of stents, with three radiopaque zones to assist in placement and visibility, while its closed cell design offers true vessel reconstruction and coil mass support.

Dr Martin Bendzus, of Cordis, said: “Patients that could hardly be treated before will be treated much more safely via an endovascular procedure with Cordis Enterprise.”

Earlier this month, Cordis announced that initiation of clinical and eduation programs regarding its sirolimus-eluting coronary stent.